ClinicalTrials.gg
Not yet recruitingNCT07257939Beyond HarmonyUpdated Sep 30, 2026

NTI164 in Autism Spectrum Disorder

A Phase 3 interventional study of NTI164 and Placebo in Autism, Autism Spectrum Disorder and Autism Disorder, sponsored by Fenix Innovation Group. Not yet recruiting at 3 sites in Australia. Open to participants aged 6 Years to 21 Years. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Fenix Innovation Group · Phase 3, Interventional, and Treatment

Updated Sep 30, 2026Enrollment updatedEligibility revised+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
6 Years to 21 Years
Sex
All
01

Study summary

This is a double-blind, randomised, placebo-controlled study investigating the efficacy of a full-spectrum medicinal cannabis plant extract on core and associated ASD symptoms over placebo. Participants will be randomly allocated to either NTI164 or placebo at a 1:1 ratio and blood samples will be collected and surveys completed at baseline and Week 16. This study will expand efficacy and safety data of NTI164 and provide additional mechanism of action data of NTI164 in this patient cohort.

Read the detailed description

Participants will be recruited from sites across Australia and will have a diagnosis of ASD Level II or III, as well as satisfying other inclusion/exclusion criteria. The primary objective is to assess efficacy of 16 weeks of daily oral administration of NTI164 on core ASD symptoms compared to placebo. The secondary objectives are to further expand the safety data of NTI164 in this patient cohort, and assess the changes in other associated symptoms of ASD following NTI164.

02

Conditions studied

  • Autism
  • Autism Spectrum Disorder
  • Autism Disorder

Keywords

  • Cannabis
  • NTI164
  • Autism spectrum disorder
03

In context

Autistic Disorder

1,033 studies on the registry are indexed under Autistic Disorder; 269 are open to participants now.

This study's planned enrollment of 200 is above the median of 49 across 813 interventional studies indexed under Autistic Disorder.

Browse Autistic Disorder studies →

Lead sponsor

Fenix Innovation Group is the lead sponsor of 7 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Sep 30, 2026. See what changed

Ages eligible
6 Years to 21 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant is aged 6 years to 21 years (inclusive).
  2. Participant is at a healthy weight at the discretion of the Principal Investigator.
  3. Written from parent or legal guardian according to the local law.
  4. Participants can comply with trial requirements.
  5. According the , 5th Edition (DSM-5) criteria the participant has a diagnosis of Level II or III ASD confirmed by a validated assessment tool.
  6. All treatments including medications and therapies for ASD related symptoms must have been stable for 12 weeks before enrolment and for the duration of the trial wherever possible.
  7. Participants must be able to swallow liquid.
  8. Consent giver must be able to understand the requirements of the study.

Exclusion criteria

Exclusion Criteria:

  1. Current diagnosis of bipolar disorder, psychosis, schizophrenia, schizoaffective disorder, or active major depression.
  2. Has a diagnosis other than ASD that dominates the clinical presentation (e.g., ADHD).
  3. Has a degenerative condition.
  4. Changes in anticonvulsive therapy within the last 12 weeks.
  5. Taking omeprazole, lansoprazole, tolbutamide, warfarin, sirolimus, everolimus, temsirolimus, tacrolimus, clobazam, repaglinide, pioglitazone, rosiglitazone, montelukast, bupropion, or efavirenz.
  6. Currently using or has used recreational or medicinal cannabis, cannabinoid-based medications (including Sativex®, or Epidiolex®) within the 12 weeks prior to screening and is unwilling to abstain for the duration of the trial.
  7. Participant has any known or suspected to cannabinoids or any of the .
  8. Participant has moderately impaired hepatic function at screening, defined as serum (ALT) or aspartate aminotransferase (AST) > 2 × (ULN) or total (TBL) > 2 × ULN. This criterion can only be confirmed once the laboratory results are available; participants enrolled into the trial who are later found to meet this criterion must be screen-failed.
  9. Participant is male and fertile (i.e., after puberty unless permanently sterile by bilateral orchidectomy) unless willing to ensure that they use male (condom) or remain sexually abstinent during the trial and for 12 weeks thereafter.
  10. Participant is female and with (i.e., following menarche and until becoming for ≥ 12 consecutive months unless permanently sterile by hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) unless willing to ensure that they use a highly effective method of birth control (e.g., hormonal contraception, intrauterine device/hormone-releasing system, bilateral tubal occlusion, vasectomised partner, sexual abstinence) during the trial and for 12 weeks thereafter.
  11. Female participant who is pregnant (positive pregnancy test), lactating or planning pregnancy during the course of the trial or within 12 weeks thereafter.
  12. Participant had brain surgery or traumatic brain injury within 1 year of screening.
  13. Participant has any other significant disease or disorder which, in the opinion of the Investigator, may either put the participant, other participants, or site staff at risk because of participation in the trial, may influence the result of the trial, or may affect the participant's ability to take part in the trial.
  14. Any abnormalities identified following a physical examination of the participant that, in the opinion of the Investigator, would jeopardise the safety of the participant if they took part in the trial.
  15. Any history of suicidal behaviour (lifelong) or any suicidal ideation of type 4 or 5 on the Columbia-Suicide Severity Rating Scale (C-SSRS) in the last 12 weeks or at screening or randomisation.
  16. Participant has donated blood during the past 12 weeks and is unwilling to abstain from donation of blood during the trial.
  17. Participant has any known or suspected history of alcohol or substance abuse or positive drugs of abuse test at screening (not justified by a known concurrent medication).
  18. Participant has previously been enrolled into this trial.
  19. Participant has plans to travel outside their country of residence during the trial, unless the participant has confirmation that the product is permitted in the destination country/state.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Active

    NTI164

    Drug: NTI164

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo

Interventions

  • DrugNTI164

    A CBDA-dominant full-spectrum medicinal cannabis plant extract with extremely low THC.

    Also known as: FEN164

  • DrugPlacebo

    Placebo oil suspension

06

What researchers measure

Primary outcomes

  1. Vineland Adaptive Behaviour Scales, 3rd Edition (Vineland-3)

    Used to measure functioning across 3 core domains, Communication, Daily Living Skills, and Socialisation, as well as 2 optional domains, Motor Skills and Maladaptive Behaviour. The core domains sum to a total Adaptive Behaviour Composite. Scores are between 20-160, higher scores indicate better outcomes.

    Time frame: Baseline, Week 16

Secondary outcomes

  1. Social Responsiveness Scale, 2nd Edition (SRS-2)

    Captures overall change in core ASD symptoms across domains including social awareness, social cognition, social communication, social motivation, and restricted and repetitive behaviours. Scores are between 0-195, and higher scores indicate greater impairment.

    Time frame: Baseline, Week 16

  2. Clinical Global Impression - Improvement (CGI-I)

    Provides a clinician-rated global assessment of improvement at a given time point following an intervention. 1-3 = improvement, 4 = no change, 5-7 = worsening.

    Time frame: Baseline, Week 16

  3. Clinical Global Impression - Severity (CGI-S)

    Evaluates a clinician's impression of disease severity at a given time point from a scale of 1-7. A higher score indicates greater impairment/disease severity.

    Time frame: Baseline, Week 16

  4. Anxiety, Depression, and Mood Scale (ADAMS)

    Measures emotional and behavioural disturbances frequently comorbid with ASD. Assesses 5 domains (Manic/hyperactive Behaviour, Depressed Mood, Social Avoidance, General Anxiety, and Compulsive Behaviour). Scores are between 0-84, with higher scores indicating greater impairment.

    Time frame: Baseline, Week 16

  5. Autism Family Experience Questionnaire (AFEQ)

    Captures caregiver perceptions of changes in family impact, child wellbeing, and support burden. Scores range from 48-240, with higher scores indicating worse family outcomes.

    Time frame: Baseline, Week 16

  6. Sleep Disturbances Scale for Children (SDSC)

    Evaluates treatment-related changes in sleep quality and sleep-wake behaviours. Assesses 6 domains (Disorders of Initiating and Maintaining Sleep, Sleep Breathing Disorders, Disorders of Arousal, Sleep Wake Transition Disorders, Disorders of Excessive Somnolence, and Sleep Hyperhidrosis). Scores range from 26-130, with higher scores indicating greater impairment and issues around sleep.

    Time frame: Baseline, Week 16

  7. EQ-5D-Y-5L

    Measures broader wellbeing and day-to-day function, as well as quality of life (QoL), from a caregiver-reported perspective. Assesses health in 5 domains (Mobility, Usual Activities, Self-care, Pain/discomfort, and Anxiety/depression), and QoL. Scores range from 0-1, with 0 = the worst health possible and 1 = the best possible health state. The higher the score, the better the health state.

    Time frame: Baseline, Week 16

  8. Anxiety Scale for Children with ASD, Parent edition (ASC-ASD-P)

    Evaluates changes in anxiety symptoms and emotional regulation. It is used to detect symptoms of anxiety in youth with ASD and assesses 4 domains (Performance Anxiety, Uncertainty, Anxious Arousal, and Separation Anxiety). Scores range from 0-72, with higher scores indicating greater impairment.

    Time frame: Baseline, Week 16

  9. Aberrant Behaviour Checklist (ABC)

    Assesses challenging behaviours and behavioural regulation relevant to ASD functioning. Measures impairment across 5 domains (Irritability, Lethargy/social Withdrawal, Stereotypic Behaviour, Hyperactivity/non-compliance, and Inappropriate Speech. Scores range from 0-174, with higher scores indicating greater impairment.

    Time frame: Baseline, Week 16

Other outcomes

  1. Research samples - transcriptomics

    To further clarify the mechanism of action of NTI164, both bulk and single-cell RNA sequencing will be performed on peripheral blood mononuclear cells (PBMCs) from patients at specified time points. This will provide additional information regarding which genes are being expressed in patients at either abnormally low or high levels compared to a non-ASD population, and the effects NTI164 has on gene expression. This workflow includes RNA extraction, depletion of ribosomal RNA via hybrid capture, library preparation, and sequencing. Cleaned sequence reads will then be aligned against the Homo sapiens genome (Build version hg38) and STAR aligner (v2.5.3a) will be used to map unique reads to the genomic sequences. This is exploratory so genes of interest cannot be identified in advance.

    Time frame: Baseline, Week 16

  2. Research bloods - proteomics (and phosphoproteomics)

    To further clarify the mechanism of action of NTI164, proteomics and phosphoproteomics will be performed on peripheral blood mononuclear cells (PBMCs) from patients at specified time points. This will provide additional information regarding which proteins are being expressed at either abnormally low or high levels compared to a non-ASD population, as well as how extensively these proteins are phosphorylated compared to a non-ASD population, and the effects NTI164 has on protein expression and phosphorylation. Samples will be tagged using the TMTpro system and hydrophilic ion liquid chromatography fractionation performed. This is exploratory so proteins of interest cannot be identified in advance.

    Time frame: Baseline, Week 16

  3. Research bloods - Methylomics

    To further clarify the mechanism of action of NTI164, methylomics will be performed on whole blood from patients at specified time points. This will provide additional information on methylation patterns (e.g. addition of a methyl group to histones or DNA) in patients compared to non-patients, and how NTI164 effects this type of epigenetic modification and how genes of interest may be regulated. This is exploratory so patterns of interest cannot be identified in advance. Genome-wide methylation will be assessed using the Illumina MethylationEPIC v2.0 BeadChip (or the latest version if a new version is available to the study team at the time of analysis).

    Time frame: Baseline, Week 16

  4. Research bloods - cytokine assay

    To further clarify the mechanism of action of NTI164, a cytokine assay investigating a panel of inflammatory markers will be performed on plasma from patients at specified time points. The cytokine assay will likely be the LEGENDplex Human Neuroinflammation Panel 1 (13 plex). Cytokines investigated with this panel include VILIP-1, CCL2, sTREM-2, b-NGF, TGF-b1, TNF-a, IL-6, s-TREM-1, sRAGE, CX3CL1, VEGF, BDNF, and IL-18.

    Time frame: Baseline, Week 16

07

Study locations

3 sites
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Jul 2029, 33 months later.

Of 15 phase 3 interventional studies under Autistic Disorder, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 48. This study's planned 33 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2025
First posted
Dec 2, 2025
StartEst.
Sep 30, 2026
Primary completionEst.
Jul 1, 2029
CompletionEst.
Jul 1, 2030
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added
Show 2 added (2 Australia)
  • Children's Hospital Queensland · Brisbane, Australia
  • Sunshine Coast University Hospital · Sunshine Coast, Australia
Sep 30, 2026
Enrollment
98→200
Sep 30, 2026
Eligibility
Maximum age 25 Years→21 Years; 1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedParticipant is aged 6 years to 2521 years (inclusive).
Sep 30, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Social Responsiveness Scale, 2nd Edition (SRS-2)Now Vineland Adaptive Behaviour Scales, 3rd Edition (Vineland-3)Time frame: Baseline, Week 16
Sep 30, 2026
Secondary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Vineland Adaptive Behaviour Scales, 3rd Edition (Vineland-3)Now Social Responsiveness Scale, 2nd Edition (SRS-2)Time frame: Baseline, Week 16
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    2 sites added
    Show 2 added (2 Australia)
    • Children's Hospital Queensland · Brisbane, Australia
    • Sunshine Coast University Hospital · Sunshine Coast, Australia
    Enrollment 98→200
    Eligibility Maximum age 25 Years→21 Years; 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedParticipant is aged 6 years to 2521 years (inclusive).
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Social Responsiveness Scale, 2nd Edition (SRS-2)Now Vineland Adaptive Behaviour Scales, 3rd Edition (Vineland-3)Time frame: Baseline, Week 16
    Secondary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Vineland Adaptive Behaviour Scales, 3rd Edition (Vineland-3)Now Social Responsiveness Scale, 2nd Edition (SRS-2)Time frame: Baseline, Week 16
    + 2 other changes: identifiers and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07257939
Lead sponsor
Fenix Innovation Group
Collaborators
Neurotech International Limited
Responsible party
Sponsor
First posted
Dec 2, 2025
Start date
Sep 30, 2026 (estimated)
Primary completion
Jul 1, 2029 (estimated)
Completion
Jul 1, 2030 (estimated)
Last update
Sep 30, 2026

Study contacts

Kanan Sharma
Contact
monashchildrensctc@monashhealth.org
+61395946666
Michael C Fahey
Contact

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: NTI164

Start the discussion